---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-004309"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2022-02-14T23:59:59+00:00"
generated_at: "2026-06-27T08:38:17.719482+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics grants 694,424 RSUs tied to Roche collaboration milestones

## Summary
- RSUs awarded to employees and executive officers; half vest over 4 years, half upon milestone achievement under Roche License Agreement.
- Roche deal includes $50M upfront payment and up to $620M in developmental, regulatory, and commercial milestones.
- OpRegen cell therapy for ocular disorders (dry AMD with geographic atrophy) is subject of the exclusive worldwide license.
- Tiered double-digit royalties on net sales of OpRegen, subject to intellectual property and competitive product offsets.
- RSUs granted under 2021 Equity Incentive Plan; continued vesting requires continuous service.

## SEC filing metadata
- accession: 0001493152-22-004309
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2022-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315222004309/0001493152-22-004309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315222004309/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-004309
- JSON: https://secwatch.observer/filing/0001493152-22-004309.json
- Plain text: https://secwatch.observer/filing/0001493152-22-004309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.